Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 2Q

Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 2Q

2Q Revenues: $5.9 billion (-3%)

2Q Earnings: $1.6 billion (-12%)

YTD revenues: $11.3 billion (-5%)

YTD Earnings: $3.0 billion (-41%)

Comments: Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%). Cozaar and Hyzaar sales were $906 million (-4%). Gardasil sales were $268 million (-18%). Rotateq sales were $126 million (-29%). Januvia sales were up 38% to $462 million. Isentress sales were $172 million (+123%). Revenue from the AstraZeneca alliance for certain products including Nexium, was $386 million in the quarter. Restructuring costs in the quarter, primarily related to employee separations, were $37 million. R&D expenses were $1.4 billion for the quarter (+19%), reflecting an increase in the company’s external licensing activity.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters